Terese C Hammond, Marco A Purbhoo, Sapana Kadel, Jerome Ritz, Sarah Nikiforow, Heather Daley, Kit Shaw, Koen van Besien, Alexandra Gomez-Arteaga, Don Stevens, Waldo Ortuzar, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Reed Masakayan, Burcu Yigit, Shannon Boi, Kah Teong Soh, John Chamberland, Xin Song, Yu Qin, Ilya Mishchenko, Maurice Kirby, Valeriia Nasonenko, Alexa Buffa, Jennifer S Buell, Dhan Chand, Marc van Dijk, Justin Stebbing, Mark A Exley
Invariant natural killer T (iNKT) cells, a unique T cell population, lend themselves for use as adoptive therapy due to diverse roles in orchestrating immune responses. Originally developed for use in cancer, agenT-797 is a donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy. We conducted an open-label study in virally induced acute respiratory distress syndrome (ARDS) caused by the severe acute respiratory syndrome-2 virus (trial registration NCT04582201). Here we show that agenT-797 rescues exhausted T cells and rapidly activates both innate and adaptive immunity...
February 6, 2024: Nature Communications